There’s a resurgence of sexually transmitted infections (STIs) in South Africa and around the world. The Gauteng Department of Health recently reported an increase of newly acquired STIs, in particular gonorrhoea and chlamydia. This spike in cases call for management guidelines and awareness programmes to be reviewed, reports Ufrieda Ho.
Newly announced results of a pivotal phase 3 trial have demonstrated the effectiveness of a new treatment for gonorrhoea. The medicine, zoliflodacin, is the first new drug developed to treat gonorrhoea in over 30 years. More than half of the 930 patients in the trial were from South Africa. Catherine Tomlinson reports.
Last year, Spotlight reported that taking a widely available antibiotic, doxycycline after condomless sex can reduce the risk of contracting three different sexually transmitted infections (STIs). Elri Voigt unpacks some further results from three studies presented at CROI2023 on Doxycycline as post-exposure prophylaxis (PEP) for STI prevention.
Taking the antibiotic doxycycline after condomless sex can reduce the risk of contracting three different sexually transmitted infections (STIs), according to a study presented last week at the AIDS 2022 conference in Montreal, Canada. Elri Voigt unpacks the study findings and asks local experts what it might mean for combatting STIs in South Africa.
Despite the global emergence of highly resistant strains of gonorrhoea, including untreatable variants, a new antibiotic for the disease has not been developed in over half a century. In January, a trial began in South Africa and other countries for a new gonorrhoea antibiotic. But what is gonorrhoea? How significant is the problem in South Africa and among those living with HIV? Do we have resistant strains too? Experts report a grim situation, but with hope on the horizon. Amy Green reports.